Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01574222 · ClinicalTrials.gov registry record · Phase 1
A Vaccine Trial for Patients With Stage IIIB, IV, or Recurrent Non-Small Cell Lung Cancer
A Phase 1 study, sponsored by VA Office of Research and Development.
- Terminated
- Registry status
- Phase 1
- Development phase
- 1
- Enrollment target
NCT01574222: Clinical Trial Phase 1 study, sponsored by VA Office of Research and Development.
NCT01574222 is a Phase 1 study that was terminated before completion, run by VA Office of Research and Development. The registered enrollment target is 1 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01574222, a Phase 1 study, was terminated before completion, sponsored by VA Office of Research and Development.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 1 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the dose that the vaccine can be given safely to patients when injected directly into the lung tumor, without any serious side effects.
Primary Outcome
Toxicity as measured by NCI Common Toxicity Criteria
Interventions
- BIOLOGICAL autologous dendritic cell adenovirus CCL21 vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2011-10-01 |
| Est. Completion | 2017-03-01 |
| Phase | Phase 1 |
Why NCT01574222 stopped before completion
NCT01574222 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 1 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 1 intervention - of which autologous dendritic cell adenovirus CCL21 vaccine is the first listed.
NCT01574222 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01574222 about?
NCT01574222 is a clinical study titled "A Vaccine Trial for Patients With Stage IIIB, IV, or Recurrent Non-Small Cell Lung Cancer". The purpose of this study is to determine the dose that the vaccine can be given safely to patients when injected directly into the lung tumor, without any serious side effects.
What is the current status of trial NCT01574222?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 1 participants. The study started on 2011-10-01. Estimated completion is 2017-03-01.
What interventions are being tested in trial NCT01574222?
The interventions under investigation include: autologous dendritic cell adenovirus CCL21 vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT01574222?
This trial is sponsored by VA Office of Research and Development, which has 1,668 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01574222's enrollment target sits among peer trials
1 2001st of 2000 the lowest of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI